Amryt Pharma plc Book Value 2011-2026 | AMYT

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Amryt Pharma plc

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
357 M	66.1 M	132 M	-3.7 M	26.3 M	34.7 M	16.5 M	55.9 M	42.8 M	259 K	1.09 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
357 M	-3.7 M	66.2 M

Quarterly Book Value Amryt Pharma plc

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	357 M	-	-	-	66.1 M	-	-	-	132 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
357 M	66.1 M	185 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Amphastar Pharmaceuticals AMPH	789 M	$ 19.53	-0.2 %	$ 913 M	USA
Amarin Corporation plc AMRN	459 M	$ 14.67	-0.07 %	$ 6.09 B	Irlanda
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Aileron Therapeutics ALRN	54.4 M	-	10.36 %	$ 9.8 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Cabaletta Bio CABA	112 M	$ 2.82	1.44 %	$ 283 M	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Editas Medicine EDIT	27.3 M	$ 2.32	-	$ 206 M	USA
Enlivex Therapeutics Ltd. ENLV	23.6 M	$ 1.09	-9.17 %	$ 22.4 M	Israel
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Eton Pharmaceuticals ETON	26.2 M	$ 23.45	-1.64 %	$ 631 M	USA
EyePoint Pharmaceuticals EYPT	306 M	$ 13.06	0.08 %	$ 957 K	USA
Esperion Therapeutics ESPR	-302 M	$ 2.85	3.26 %	$ 592 M	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Equillium EQ	28.6 M	$ 2.06	-	$ 118 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	427 M	$ 1.29	-3.01 %	$ 329 M	Britain
Atreca BCEL	78.4 M	-	-11.76 %	$ 5.79 M	USA
BeiGene, Ltd. BGNE	4.36 B	-	0.49 %	$ 251 B	Cayman-islands
Harmony Biosciences Holdings HRMY	870 M	$ 27.44	-0.54 %	$ 1.58 B	USA
bluebird bio BLUE	195 M	-	-	$ 546 M	USA
Heron Therapeutics HRTX	14.3 M	$ 0.83	3.62 %	$ 138 M	USA
BioDelivery Sciences International BDSI	188 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	57.1 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	286 M	-	-	$ 3.74 B	USA
Iterum Therapeutics ITRM	-4.08 M	$ 0.18	2.33 %	$ 3.55 M	Irlanda
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Avid Bioservices CDMO	60.9 M	-	-	$ 789 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Johnson & Johnson JNJ	81.5 B	$ 239.24	-0.29 %	$ 576 B	USA
Bellerophon Therapeutics BLPH	2.53 M	-	-74.18 %	$ 955 K	USA
Kala Pharmaceuticals KALA	12.3 M	$ 0.2	-6.67 %	$ 759 K	USA
CRISPR Therapeutics AG CRSP	1.92 B	$ 47.55	0.98 %	$ 4.28 B	Schweiz